Sibutramine: Balancing weight loss benefit and possible cardiovascular risk

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 18, Issue 5, 2008, Pages 337-341

  de Simone, Giovanni ^a   D'Addeo, Gianpaolo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; ANTIDEPRESSANT AGENT; CYCLOBUTANE DERIVATIVE; SIBUTRAMINE;

CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; EATING; EDITORIAL; EVIDENCE BASED MEDICINE; HOSPITALIZATION; HUMAN; OBESITY; PATHOPHYSIOLOGY; PATIENT SELECTION; RISK ASSESSMENT; WEIGHT REDUCTION;

ANTIDEPRESSIVE AGENTS; APPETITE DEPRESSANTS; CARDIOVASCULAR DISEASES; CYCLOBUTANES; EATING; EVIDENCE-BASED MEDICINE; HUMANS; OBESITY; PATIENT SELECTION; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; WEIGHT LOSS;

EID: 44449133060     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2008.03.008     Document Type: Editorial

References (48)

1. Heal D.J., Aspley S., Prow M.R., Jackson H.C., Martin K.F., and Cheetham S.C. Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Int J Obes Relat Metab Disord 22 Suppl. 1 (1998) S18-S28
2. Heal D.J., Frankland A.T., Gosden J., Hutchins L.J., Prow M.R., Luscombe G.P., et al. A comparison of the effects of sibutramine hydrochloride, bupropion and methamphetamine on dopaminergic function: evidence that dopamine is not a pharmacological target for sibutramine. Psychopharmacology (Berl) 107 (1992) 303-309
3. Luscombe G.P., Hopcroft R.H., Thomas P.C., and Buckett W.R. The contribution of metabolites to the rapid and potent downregulation of rat cortical beta-adrenoceptors by the putative antidepressant sibutramine hydrochloride. Neuropharmacology 28 (1989) 129-134
4. Luque C.A., and Rey J.A. Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Ann Pharmacother 33 (1999) 968-978
5. Jackson H.C., Bearham M.C., Hutchins L.J., Mazurkiewicz S.E., Needham A.M., and Heal D.J. Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat. Br J Pharmacol 121 (1997) 1613-1618
6. Hansen D.L., Toubro S., Stock M.J., Macdonald I.A., and Astrup A. Thermogenic effects of sibutramine in humans. Am J Clin Nutr 68 (1998) 1180-1186
7. Walsh K.M., Lean E., and Lean M.E. The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females. Int J Obes Relat Metab Disord 23 (1999) 1009-1015
8. Cinti S. The role of brown adipose tissue in human obesity. Nutr Metab Cardiovasc Dis 16 (2006) 569-574
9. Bray G.A., Blackburn G.L., Ferguson J.M., Greenway F.L., Jain A.K., Mendel C.M., et al. Sibutramine produces dose-related weight loss. Obes Res 7 (1999) 189-198
10. Hanotin C., Thomas F., Jones S.P., Leutenegger E., and Drouin P. Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study. Int J Obes Relat Metab Disord 22 (1998) 32-38
11. McMahon F.G., Weinstein S.P., Rowe E., Ernst K.R., Johnson F., and Fujioka K. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens 16 (2002) 5-11
12. James W.P., Astrup A., Finer N., Hilsted J., Kopelman P., Rossner S., et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 356 (2000) 2119-2125
13. Dujovne C.A., Zavoral J.H., Rowe E., Mendel C.M., and Sibutramine Study Group. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo controlled study in 322 overweight and obese patients with dyslipidemia. Am Heart J 142 (2001) 489-497
14. Wirth A., and Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 286 (2001) 1331-1339
15. McMahon F.G., Fujioka K., Singh B.N., Mendel C.M., Rowe E., Rolston K., et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 160 (2000) 2185-2191
16. Zannad F., Gille B., Grentzinger A., Bruntz J.F., Hammadi M., Boivin J.M., et al. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. Am Heart J 144 (2002) 508-515
17. de Simone G., Romano C., De Caprio C., Contaldo F., Salanitri T., di Luzio Paparatti U., et al. Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects. Nutr Metab Cardiovasc Dis 15 (2005) 24-30
18. Fujioka K., Seaton T.B., Rowe E., Jelinek C.A., Raskin P., Lebovitz H.E., et al., Sibutramine/Diabetes Clinical Study Group. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2 (2000) 175-187
19. Redmon J.B., Raatz S.K., Reck K.P., Swanson J.E., Kwong C.A., Fan Q., et al. One-year outcome of a combination of weight loss therapies for subjects with type 2 diabetes: a randomized trial. Diabetes Care 26 9 (2003) 2505-2511
20. Ersoz H.O., Ukinc K., Baykan M., Erem C., Durmus I., Hacihasanoglu A., et al. Effect of low-dose metoprolol in combination with sibutramine therapy in normotensive obese patients: a randomized controlled study. Int J Obes Relat Metab Disord 28 (2004) 378-383
21. Van Gaal L.F., Wauters M.A., Peiffer F.W., and De Leeuw I.H. Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal/visceral fat reduction?. Int J Obes Relat Metab Disord 22 Suppl. 1 (1998) S38-S40
22. Kamel E.G., McNeill G., and Van Wijk M.C. Change in intra-abdominal adipose tissue volume during weight loss in obese men and women: correlation between magnetic resonance imaging and anthropometric measurements. Int J Obes Relat Metab Disord 24 (2000) 607-611
23. Faria A.N., Ribeiro Filho F.F., Kohlmann N.E., Gouvea Ferriera S.R., and Zanella M.T. Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients. Diabetes Obes Metab 7 (2005) 246-253
24. Valsamakis G., McTernan P.G., Chetty R., Al Daghiti N., Field A., Hanif W., et al. Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism 53 (2004) 430-434
25. Filippatos T.D., Kiortsis D.N., Liberopoulos E.N., Mikhailidis D.P., and Elisaf M.S. A review of the metabolic effects of sibutramine. Curr Med Res Opin 21 (2005) 457-468
26. Perchenet L., Hilfiger L., Mizrahi J., and Clement-Chomienne O. Effects of anorexinogen agents on cloned voltage-gated K+ channel hKv1.5. J Pharmacol Exp Ther 298 (2001) 1108-1111
27. Guven A., Koksal N., Cetinkaya A., Sokmen G., and Ozdemir R. Effects of the sibutramine therapy on pulmonary artery pressure in obese patients. Diabetes Obes Metab 6 (2004) 50-55
28. Wadden T.A., Berkowitz R.I., Womble L.G., Sarwer D.B., Phelan S., Cato R.K., et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 353 20 (2005) 2111-2120
29. Berkowitz R.I., Fujioka K., Daniels S.R., Hoppin A.G., Owen S., Perry A.C., et al. Effects of sibutramine treatment in obese adolescents a randomized trial. Ann Intern Med 145 (2006) 81-90
30. Yee B.J., Phillips C.L., Banerjee D., Caterson I., Hedner J.A., and Grunstein R.R. The effect of sibutramine-assisted weight loss in men with obstructive sleep apnoea. Int J Obes (Lond) 31 (2007) 161-168
31. Gürsoy A., Erdoǧan M.F., Cin M.O., Cesur M., and Başkal N. Effects of sibutramine on blood pressure in patients with obesity and well controlled hypertension or normotension. Endocr Pract 11 (2005) 308-312
32. Gaciong Z., and Placha G. Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label observational study. J Hum Hypertens 19 (2005) 737-743
33. Berubè-Parent S., Prud'homme D., St-Pierre S., Doucet E., and Tremblay A. Obesity treatment with a progressive clinical tri-therapy combining sibutramine and a supervised diet-exercise intervention. Int J Obes 25 (2001) 1144-1153
34. Birkenfeld A.L., Schroeder C., Boschmann M., Tank J., Franke G., Luft F.C., et al. Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Circulation 106 (2002) 2459-2465
35. Jordan J., Scholze J., Matiba B., Wirth A., Hauner H., and Sharmas A.M. Influence of sibutramine on blood pressure: evidence from placebo-controlled trials. Int J Obes 29 (2005) 509-516
36. Birkenfeld A.L., Schroeder C., Pischon T., Tank J., Luft F.C., Sharma A.M., et al. Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients. Clin Auton Res 15 (2005) 200-206
37. Shechter M., Beigel R., Freimark D., Matetzky S., and Feinberg M.S. Short-term sibutramine therapy is associated with weight loss and improved endothelial function in obese patients with coronary artery disease. Am J Cardiol 97 (2006) 1650-1653
38. Scholze J., Grimm E., Herrmann D., Unger T., and Kintscher U. Optimal treatment of obesity-related hypertension: the hypertension-obesity-sibutramine (HOS) study. Circulation 115 (2007 Apr 17) 1991-1998
39. Vakili B.A., Okin P.M., and Devereux R.B. Prognostic implications of left ventricular hypertrophy. Am Heart J 141 (2001) 334-341
40. Himeno E., Nishino K., Nakashima Y., Kuroiwa A., and Ikeda M. Weight reduction regresses left ventricular mass regardless blood pressure level in obese subjects. Am Heart J 131 (1996) 313-319
41. Alpert M.A., Terry B.E., and Kelly D.L. Effect of weight loss on cardiac chamber size, wall thickness and left ventricular function in morbid obesity. Am J Cardiol 55 (1985) 783-786
42. Alpert M.A., Lambert C.R., Terry B.E., Kelly D.L., Panayiotou H., Mukerji V., et al. Effect of weight loss on left ventricular mass in nonhypertensive morbidly obese patients. Am J Cardiol 73 (1994) 918-921
43. de Simone G., Wachtell K., Palmieri V., Hille D.A., Beevers G., Dahlof B., et al. Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. Circulation 111 (2005) 1924-1931
44. Liebson P.R., Grandits G.A., Dianzumba S., Prineas R.J., Grimm Jr. R.H., Neaton J.D., et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 91 3 (1995) 698-706
45. Grassi G. Sympathetic drive as a determinant of weight loss intervention outcome strengths and limitations. Am J Hypertens 18 (2005) 1517-1518
46. Mannucci E., Dicembrini I., Rotella F., and Rotella C.M. Orlistat and sibutramine beyond weight loss. Nutr Metab Cardiovasc Dis 18 5 (2008) 342-348
47. James W.P.T. SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients. Eur Heart J Suppl 7 (2005) L44-L48
48. Torp-Pedersen C., Caterson I., Coutinho W., Finer N., Van Gaal L., Maggioni A., et al., SCOUT Investigators. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J 28 (2007) 2915-2923